La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Evelo Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Evelo Biosciences..

Evelo Biosciences (OTC:EVLO) Azioni, Catena delle Opzioni

Evelo Biosciences

Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.

EVELO BIOSCIENCES INC by Evelo Biosciences, Inc.

Evelo Biosciences Inc

<h3>Gainers</h3>
<ul>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock increased by 33.9% to $1.5 during Wednesday's pre-market session. The company's market cap stands at $3.6 million. </li>
<li>Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) shares moved upwards by 18.41% to $0.4. The market value of their outstanding shares is at $9.4 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 18.0% to $0.36. The market value of their outstanding shares is at $17.6 million. </li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) stock rose 17.45% to $0.43. The market value of their outstanding shares is at $3.3 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares moved upwards by 15.41% to $2.62. The company's market cap stands at $67.8 million. </li>
<li>Minerva Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTRS#NASDAQ">UTRS</a>) shares increased by 14.4% to $2.78. The company's market cap stands at $24.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock declined by 16.3% to $1.23 during Wednesday's pre-market session. The market value of their outstanding shares is at $138.1 million. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares declined by 12.19% to $0.51. The company's market cap stands at $2.4 million. </li>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) shares decreased by 9.31% to $1.17. The company's market cap stands at $1.2 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares fell 8.96% to $2.44. The market value of their outstanding shares is at $180.1 million. </li>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) stock declined by 8.89% to $0.35. The market value of their outstanding shares is at $6.6 million. </li>
<li>Lucy Scientific Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) stock fell 7.87% to $0.28. The company's market cap stands at $4.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALLR

BCLI

BIOL

CYTO

EVLO

LSDI

OPTN

PHIO

RANI

TENX

UTRS

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Biotech

News

Health Care

General

On December 1, 2023, Evelo Biosciences Was Notified By NASDAQ's Listing Qualifications That As A Result Of The Events Disclosed In Its Filing On November 21, The Staff Believes That The Company No Longer Has An Operating Business And Is Public Shell-8K

<h3>Gainers</h3>
<ul>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock moved upwards by 39.7% to $1.97 during Friday's regular session. The market value of their outstanding shares is at $50.9 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) stock increased by 27.72% to $1.29. The company's market cap stands at $123.6 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares rose 21.69% to $1.29. The company's market cap stands at $27.2 million. </li>
<li>Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) stock rose 18.0% to $2.95. The company's market cap stands at $143.8 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares increased by 17.62% to $18.95. The company's market cap stands at $1.4 billion. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock moved upwards by 16.66% to $0.35. The market value of their outstanding shares is at $7.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) stock fell 19.7% to $0.49 during Friday's regular session. The market value of their outstanding shares is at $9.2 million. </li>
<li>Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) shares fell 12.24% to $2.51. The market value of their outstanding shares is at $64.1 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock declined by 11.6% to $2.17. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock decreased by 11.0% to $0.61. The market value of their outstanding shares is at $11.7 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares fell 10.42% to $4.58. The company's market cap stands at $65.5 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock declined by 9.0% to $0.72. The company's market cap stands at $6.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTS

GYRE

KTTA

LIFW

LPTX

MODD

SCLX

SGHT

SNES

VIRI

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 50 points on Friday.
Following the market opening Friday, the Dow traded up 0.14% to 35,323.77 while the NASDAQ fell 0.13% to 14,247.68. The S&amp;P 500 also fell, dropping, 0.02% to 4,555.53.
Check This Out: <a href="https://www.benzinga.com/news/23/11/35938087/visa-keycorp-and-2-other-stocks-insiders-are-selling"> Visa, KeyCorp And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
Energy shares surged by 0.6% on Friday.
In trading on Friday, real estate shares fell by 0.5%.
&nbsp;
<h3>Top Headline</h3>
Amazon.com Inc.&rsquo;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) proposed acquisition of iRobot Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irbt#NASDAQ">IRBT</a>), the popular Roomba robot vacuum manufacturer, is reportedly on the verge of receiving unconditional approval from <a href="https://www.benzinga.com/news/23/11/35934729/amazons-1-4b-irobot-acquisition-set-to-get-unconditional-approval-from-eu-antitrust-authorities-repo">European Union antitrust authorities.</a>
&nbsp;
<h3>Equities Trading UP</h3>
FLJ Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flj#NASDAQ">FLJ</a>) shares shot up 137% to $0.2564 after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology.
Shares of BioNexus Gene Lab Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bglc#NASDAQ">BGLC</a>) got a boost, shooting 113% to $0.7862.
Versus Systems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vs#NASDAQ">VS</a>) shares were also up, gaining 45% to $0.24. Versus Systems announced a strategic investment from Cronus Equity Capital Group, LLC.
&nbsp;
<h3>Equities Trading DOWN</h3>
Impel Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/impl#NASDAQ">IMPL</a>) shares dropped 20% to $0.6270 after jumping 143% on Wednesday. Impel Pharmaceuticals recently announced exploration of strategic alternatives.
Shares of Evelo Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>) were down 15% to $0.51.
Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) was down, falling 13% to $0.68.
Also Check This Out:<a href="https://www.benzinga.com/news/earnings/23/11/35935872/how-to-earn-500-a-month-from-deere-stock-following-upbeat-earnings"> How To Earn $500 A Month From Deere Stock Following Upbeat Earnings</a>
&nbsp;
<h3>Commodities</h3>
In commodity news, oil traded down 1.3% to $76.11 while gold traded up 0.4% at $2,001.40.
Silver traded up 1.6% to $24.075 on Friday while copper fell 0.2% to $3.7545.
&nbsp;
<h3>Euro zone</h3>
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 gained 0.1%, London&rsquo;s FTSE 100 fell 0.2% while Spain&rsquo;s IBEX 35 Index rose 0.4% The German DAX rose 0.1% French CAC 40 climbed 0.1%, while Italy&rsquo;s FTSE MIB Index rose 0.4%.
The Ifo Business Climate indicator for Germany climbed for the second straight month to a reading of 87.3 in November, while German economy contracted by 0.1% during the third quarter. Producer prices in Spain fell by 7.8% year-over-year in October versus a revised 8.5% fall in the previous month.
&nbsp;
<h3>Asia Pacific Markets</h3>
Asian markets closed mostly lower on Friday, with Japan&rsquo;s Nikkei 225 gaining 0.52%, Hong Kong&rsquo;s Hang Seng Index falling 1.96% and China&rsquo;s Shanghai Composite Index falling 0.68%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell 0.1%.
The au Jibun Bank Japan manufacturing PMI fell to 48.1 in November from 48.7 a month ago, while annual inflation rate accelerated to 3.3% in October from 3.0% a month ago. The index of leading economic indicators in Japan was revised higher to 108.9 in September versus a flash reading of 108.7, while index of coincident economic indicators came in at 114.7 in September, matching the flash reading.
&nbsp;
<h3>Economics</h3>
The flash Composite Purchasing Managers&#39; Index for November will be released at 9:45 a.m. ET.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35938606/top-5-tech-and-telecom-stocks-that-could-blast-off-in-q4"> Top 5 Tech And Telecom Stocks That Could Blast Off In Q4</a>

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

AMZN

BGLC

IMPL

IRBT

US Stocks Mixed; Dow Gains 50 Points

Management

Regarding The Dissolution, Evelo Biosciences' Simba Gill Ceased Serving As The Company's President, CEO And President, And Marella Thorell Ceased Serving As The CFO, Secretary, Treasurer, Principal Financial Officer, And Principal Accounting Officer

<h3>Gainers</h3>
<ul>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) stock increased by 222.5% to $0.32 during Friday's regular session. As of 12:31 EST, this security is trading at a volume of 248.0 million shares, making up 22940.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.5 million. </li>
<li>Fortress Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIO#NASDAQ">FBIO</a>) stock increased by 46.85% to $2.1. Trading volume for this security as of 12:31 EST is 4.8 million, which is 4476.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.1 million. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares rose 27.64% to $2.45. Trading volume for Kodiak Sciences's stock is 3.7 million as of 12:31 EST. This is 459.9% of its average full-day volume over the last 100 days. The company's market cap stands at $128.5 million. The company's, Q3 earnings came out 3 days ago. </li>
<li>Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) stock moved upwards by 26.27% to $24.08. Trading volume for Twist Bioscience's stock is 2.4 million as of 12:31 EST. This is 253.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.3 billion. The company's, Q4 earnings came out today. </li>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) stock rose 24.62% to $2.48. Trading volume for Connect Biopharma Hldgs's stock is 163.1K as of 12:31 EST. This is 285.7% of its average full-day volume over the last 100 days. The company's market cap stands at $136.5 million. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) stock increased by 22.14% to $1.82. Ikena Oncology's stock is trading at a volume of 248.2K shares as of 12:31 EST. This is 150.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $87.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares declined by 36.4% to $4.25 during Friday's regular session. As of 12:31 EST, Vigil Neuroscience's stock is trading at a volume of 586.6K, which is 1340.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $152.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) stock decreased by 32.85% to $0.52. As of 12:31 EST, this security is trading at a volume of 1.6 million shares, making up 164.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.6 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) stock fell 21.06% to $0.58. Evelo Biosciences's stock is trading at a volume of 1.5 million shares as of 12:31 EST. This is 272.6% of its average full-day volume over the last 100 days. The company's market cap stands at $10.9 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 20.0% to $0.28. As of 12:31 EST, this security is trading at a volume of 504.6K shares, making up 327.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.3 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) shares decreased by 18.46% to $0.34. As of 12:31 EST, Tenax Therapeutics's stock is trading at a volume of 4.0 million, which is 59.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.1 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock declined by 16.18% to $2.28. The current volume of 255.9K shares is 103.8% of Solid Biosciences's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $46.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

BBLG

CNTB

FBIO

IKNA

SLDB

TWST

VIGL

Shares of Shapeways Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shpw#NASDAQ">SHPW</a>) tumbled during Wednesday&rsquo;s session following downbeat results.
Shapeways Hldgs posted an adjusted loss of $1.36 per share, versus market expectations for a loss of 95 cents per share. The company&rsquo;s quarterly sales came in at $8.37 million versus estimates of $8.75 million.
Shapeways shares fell 20.8% to $2.36 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Taysha Gene Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsha#NASDAQ">TSHA</a>) shares climbed 62.4% to $2.16 after the company reported third-quarter results.</li>
<li>Chemomab Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmmb#NASDAQ">CMMB</a>) shares jumped 55% to $0.9497 after the FDA granted CM-101 Fast Track designation for adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease.</li>
<li>Heron Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hrtx#NASDAQ">HRTX</a>) climbed 50.8% to $0.8143 after the company reported mixed third-quarter financial results and issued guidance.</li>
<li>Kinnate Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/knte#NASDAQ">KNTE</a>) rose 47.7% to $2.32. The company&rsquo;s board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition of the company.</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) gained 44.5% to $6.30. SciSparc said &#39;trial results indicated that SciSparc&#39;s proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer&#39;s patients who participated.&#39;</li>
<li>Evelo Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>) gained 36% to $0.47.</li>
<li>Babcock &amp; Wilcox Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bw#NYSE">BW</a>) climbed 34.3% to $1.75.</li>
<li>Solid Biosciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sldb#NASDAQ">SLDB</a>) shares rose 32.7% to $2.83. Solid Biosciences announced IND clearance by the FDA for duchenne muscular dystrophy gene therapy candidate SGT-003.</li>
<li>MGO Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgol#NASDAQ">MGOL</a>) shares climbed 32.4% to $0.6566 after reporting a sharp rise in third-quarter sales.</li>
<li>Beyond Air, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xair#NASDAQ">XAIR</a>) gained 28% to $1.7920.</li>
<li>AST SpaceMobile, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asts#NASDAQ">ASTS</a>) rose 28% to $4.8262 following third-quarter results.</li>
<li>Arcturus Therapeutics Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arct#NASDAQ">ARCT</a>) shares climbed 25.2% to $24.34 after the company reported a narrower third-quarter loss.</li>
<li>Vicarious Surgical Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rbot#NYSE">RBOT</a>) rose 23.7% to $0.2726.</li>
<li>CorMedix Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crmd#NASDAQ">CRMD</a>) gained 23% to $3.85 as the company posted a narrower-than-expected third-quarter loss.</li>
<li>Soluna Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slnh#NASDAQ">SLNH</a>) climbed 22% to $2.9499 following third-quarter results.</li>
<li>Atomera Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atom#NASDAQ">ATOM</a>) gained 21% to $7.08. Atomera achieved revenue milestone under first commercial license agreement.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) climbed 20.5% to $11.45.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) climbed 20% to $4.49 following third-quarter results.</li>
<li>Icosavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icvx#NASDAQ">ICVX</a>) gained 19.1% to $9.63 following strong quarterly earnings.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgmo#NASDAQ">SGMO</a>) jumped 19.1% to $0.4011.</li>
<li>Target Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgt#NYSE">TGT</a>) surged 18.2% to $130.89 after the company reported better-than-expected third-quarter financial results. The company will offer more than 10,000 items for holidays, that includes exclusives and many priced under $25.</li>
<li>iHeartMedia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ihrt#NASDAQ">IHRT</a>) gained 17.6% to $2.47. iHeartMedia and Global signed a multi-year podcast partnership deal in the UK, Ireland and US.</li>
<li>Farfetch Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ftch#NYSE">FTCH</a>) climbed 17.5% to $1.7750.</li>
<li>60 Degrees Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtp#NASDAQ">SXTP</a>) climbed 17% to $0.7605 as the company said that the FDA has granted a Type C meeting to consult on the path forward in developing the tafenoquine regimen of arakoda for hospitalized babesiosis patients.</li>
<li>V.F. Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vfc#NYSE">VFC</a>) climbed 14.3% to $17.80. JP Morgan upgraded VF from Underweight to Neutral and raised the price target from $15 to $19.</li>
<li>Chegg, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chgg#NYSE">CHGG</a>) gained 13.5% to $10.09. The company announced a $150 million buyback.</li>
<li>Heart Test Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hscs#NASDAQ">HSCS</a>) shares gained 11% to $0.1999 after jumping 16% on Tuesday.</li>
<li>MYT Netherlands Parent B.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/myte#NASDAQ">MYTE</a>) rose 11% to $2.2750 after dipping 33% on Tuesday. Mytheresa is expected to release first quarter fiscal year 2024 financial results on Nov. 28, 2023</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares climbed 8.1% to $0.5805 after jumping 16% on Tuesday.</li>
<li>Tripadvisor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trip#NASDAQ">TRIP</a>) gained 6.6% to $18.99. Bernstein upgraded TripAdvisor from Market Perform to Outperform.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sadot Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdot#NASDAQ">SDOT</a>) shares dipped 31.5% to $0.4903 after posting a wider third-quarter loss.</li>
<li>Electriq Power Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eliq#NASDAQ">ELIQ</a>) shares fell 30.3% to $0.5704 following third-quarter results.</li>
<li>Jaguar Global Growth Corporation I (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jggc#NASDAQ">JGGC</a>) shares fell 27.2% to $5.16.</li>
<li>Hanryu Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hryu#NASDAQ">HRYU</a>) fell 25.5% to $0.7001.</li>
<li>Global-e Online Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glbe#NASDAQ">GLBE</a>) fell 24.6% to $29.72 as the company reported third-quarter FY23 sales growth of 27% year-over-year, to $133.605 million, missing the consensus of $140.97 million.</li>
<li>ADDvantage Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aey#NASDAQ">AEY</a>) tumbled 23.4% to $0.2450 after posting a loss for the third quarter.</li>
<li>Vintage Wine Estates, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vwe#NASDAQ">VWE</a>) fell 23.3% to $0.5822 following quarterly results.</li>
<li>Kubient, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kbnt#NASDAQ">KBNT</a>) fell 22.8% to $0.1072 after the company announced it decided to voluntarily remove its stock and purchase warrants from the Nasdaq Capital Market due to noncompliance with listing requirements.</li>
<li>Aytu BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aytu#NASDAQ">AYTU</a>) declined 21.8% to $2.2987 following weak quarterly sales.</li>
<li>Troika Media Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trka#NASDAQ">TRKA</a>) dipped 20% to $1.24.</li>
<li>Ispire Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) declined 18.1% to $13.35 after jumping over 50% on Tuesday. The company reported a narrower loss for its first quarter.</li>
<li>Tivic Health Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tivc#NASDAQ">TIVC</a>) shares fell 18.1% to $1.7863 following downbeat sales results for the third quarter.</li>
<li>Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) dipped 15.2% to $4.24.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) declined 14.1% to $0.6581.</li>
<li>Intrusion Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intz#NASDAQ">INTZ</a>) shares fell 13.7% to $0.4571 as the company reported downbeat third-quarter financial results.</li>
<li>Peraso Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prso#NASDAQ">PRSO</a>) fell 9.6% to $0.2079. Peraso recently posted upbeat quarterly results.</li>
<li>Marpai, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrai#NASDAQ">MRAI</a>) dipped 7.7% to $0.59. Marpai recently posted a narrower loss for the third quarter.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zim#NYSE">ZIM</a>) fell 7.1% to $7.25 following quarterly results.</li>
<li>Momentus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnts#NASDAQ">MNTS</a>) fell 6% to $3.3748 after reporting weak quarterly results.</li>
<li>Alcon Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alc#NYSE">ALC</a>) fell 5.3% to $71.01 after the company reported weak third-quarter sales and narrowed its full-year forecast.</li>
<li>Intapp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inta#NASDAQ">INTA</a>) shares declined 4.4% to $38.99. Intapp announced launch of underwritten secondary offering of aggregate of 5 million shares by selling stockholders.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/23/11/35801579/top-3-energy-stocks-that-may-implode-in-q4"> Top 3 Energy Stocks That May Implode In Q4</a>

ARCT

ASTS

ATOM

AYTU

BTDR

CHGG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CRMD

DADA

EGOX

ELIQ

FTCH

GLBE

HRTX

HRYU

HSCS

ICVX

IHRT

INTA

INTZ

ISPR

JGGC

KBNT

KNTE

MGOL

MNTS

MRAI

MYTE

PRSO

RBOT

SDOT

SGMO

SHPW

SLNH

SPRC

SXTP

TIVC

TRIP

TRKA

TSHA

VLCN

Vintage Wine Estates, Inc. - Common Stock

XAIR

Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock moved upwards by 63.0% to $0.88 during Wednesday's regular session. As of 12:31 EST, Heron Therapeutics's stock is trading at a volume of 15.8 million, which is 750.5% of its average full-day volume over the last 100 days. The company's market cap stands at $123.8 million. The company's, Q3 earnings came out yesterday. </li>
<li>Kinnate Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNTE#NASDAQ">KNTE</a>) shares increased by 57.32% to $2.47. The current volume of 55.3 million shares is 35889.2% of Kinnate Biopharma's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $116.3 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 34.5% to $2.3. As of 12:31 EST, this security is trading at a volume of 913.3K shares, making up 1243.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $33.9 million. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) stock moved upwards by 33.54% to $4.18. As of 12:31 EST, Cormedix's stock is trading at a volume of 6.3 million, which is 1245.5% of its average full-day volume over the last 100 days. The company's market cap stands at $229.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) shares rose 30.09% to $0.81. Trading volume for this security as of 12:31 EST is 1.7 million, which is 87.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $182.5 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) shares increased by 27.21% to $0.44. As of 12:31 EST, Evelo Biosciences's stock is trading at a volume of 2.9 million, which is 702.9% of its average full-day volume over the last 100 days. The company's market cap stands at $8.3 million. The company's, Q3 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock fell 22.1% to $2.29 during Wednesday's regular session. Trading volume for Aytu BioPharma's stock is 217.6K as of 12:31 EST. This is 138.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock declined by 17.74% to $1.79. Tivic Health Systems's stock is trading at a volume of 541.0K shares as of 12:31 EST. This is 34.4% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock decreased by 16.92% to $0.89. BioCardia's stock is trading at a volume of 5.7 million shares as of 12:31 EST. This is 265.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.2 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock declined by 12.84% to $0.28. Trading volume for TransCode Therapeutics's stock is 1.5 million as of 12:31 EST. This is 26.2% of its average full-day volume over the last 100 days. The company's market cap stands at $5.5 million. </li>
<li>Homology Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIXX#NASDAQ">FIXX</a>) shares declined by 12.75% to $0.89. As of 12:31 EST, Homology Medicines's stock is trading at a volume of 561.5K, which is 364.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock declined by 11.5% to $2.31. The company's market cap stands at $31.6 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCDA

FIXX

GOSS

INTS

MIRA

RNAZ

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares moved upwards by 481.0% to $15.92 during Monday's regular session. MSP Recovery's stock is trading at a volume of 44.7 million shares as of 12:30 EST. This is 2105.5% of its average full-day volume over the last 100 days. The company's market cap stands at $213.3 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares moved upwards by 64.26% to $0.61. Cardio Diagnostics Hldgs's stock is trading at a volume of 69.7 million shares as of 12:30 EST. This is 1967.8% of its average full-day volume over the last 100 days. The company's market cap stands at $11.5 million. </li>
<li>Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) stock moved upwards by 26.29% to $1.47. Trading volume for Aileron Therapeutics's stock is 496.4K as of 12:30 EST. This is 1677.1% of its average full-day volume over the last 100 days. The company's market cap stands at $7.1 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares rose 25.9% to $0.85. As of 12:30 EST, Candel Therapeutics's stock is trading at a volume of 62.8K, which is 262.1% of its average full-day volume over the last 100 days. The company's market cap stands at $24.5 million. </li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) shares increased by 25.8% to $2.34. The company's market cap stands at $19.8 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares moved upwards by 23.08% to $3.2. As of 12:30 EST, this security is trading at a volume of 447.0K shares, making up 345.4% of its average full-day volume over the last 100 days. The company's market cap stands at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares fell 56.4% to $0.13 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 59.4 million shares, making up 101.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.8 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) stock declined by 24.89% to $13.43. As of 12:30 EST, this security is trading at a volume of 1.5 million shares, making up 226.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $948.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) stock declined by 23.36% to $39.3. MoonLake's stock is trading at a volume of 3.5 million shares as of 12:30 EST. This is 685.7% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 billion. </li>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) stock declined by 19.98% to $0.34. Trading volume for Evelo Biosciences's stock is 1.4 million as of 12:30 EST. This is 391.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.4 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares fell 18.29% to $1.65. As of 12:30 EST, Oncology Institute's stock is trading at a volume of 259.5K, which is 129.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $120.4 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares decreased by 18.24% to $1.39. Trading volume for this security as of 12:30 EST is 174.0K, which is 393.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALRN

CADL

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MLTX

NVOS

ONVO

PXMD

SYBX

ZNTL

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) stock rose 48.5% to $0.46 during Friday's regular session. Trading volume for Evelo Biosciences's stock is 4.0 million as of 13:30 EST. This is 1695.5% of its average full-day volume over the last 100 days. The company's market cap stands at $8.6 million. </li>
<li>Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) stock moved upwards by 45.81% to $3.13. As of 13:30 EST, Werewolf Therapeutics's stock is trading at a volume of 27.1 million, which is 24005.4% of its average full-day volume over the last 100 days. The company's market cap stands at $111.7 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) shares rose 32.67% to $1.34. Trading volume for this security as of 13:30 EST is 703.0K, which is 444.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $36.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares rose 31.22% to $0.52. The current volume of 411.1K shares is 892.9% of Kazia Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $12.4 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) shares increased by 29.91% to $0.8. Dermata Therapeutics's stock is trading at a volume of 320.6K shares as of 13:30 EST. This is 278.8% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) stock rose 29.9% to $0.34. Trading volume for this security as of 13:30 EST is 50.7 million, which is 88.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $56.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) stock declined by 32.4% to $2.51 during Friday's regular session. Trading volume for this security as of 13:30 EST is 294.2K, which is 4972.1% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million. </li>
<li>Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) shares fell 26.83% to $0.7. The current volume of 3.5 million shares is 384.2% of Panbela Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $2.0 million. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock fell 16.29% to $14.14. The current volume of 11.6 million shares is 530.9% of Agilon Health's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $5.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock fell 15.7% to $0.68. Virios Therapeutics's stock is trading at a volume of 993.8K shares as of 13:30 EST. This is 169.8% of its average full-day volume over the last 100 days. The company's market cap stands at $13.1 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) stock fell 13.95% to $3.27. Trading volume for this security as of 13:30 EST is 785.7K, which is 114.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $42.5 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares declined by 13.94% to $1.05. The market value of their outstanding shares is at $22.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

Envoy Medical, Inc. - Class A Common Stock

COCH

DRIO

DRMA

HOWL

KZIA

NEXI

PBLA

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30.</a>
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>Better Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bttx#NASDAQ">BTTX</a>)</h3>
<ul>
<li>Better Therapeutics recently announced the launch of AspyreRxTM to treat adults with Type 2 diabetes. The company&rsquo;s stock has a <a href="https://www.benzinga.com/quote/BTTX">52-week low of $0.14 </a>.</li>
<li>RSI Value: 27.85</li>
<li>BTTX Price Action: Shares of Better Therapeutics fell 6.1% to close at $0.15 on Thursday.</li>
</ul>
<h3>Heart Test Laboratories Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hscs#NASDAQ">HSCS</a>)</h3>
<ul>
<li>On Sept. 18, Heart Test Laboratories entered into an equity distribution agreement with Maxim Group as sales agent. It <a href="https://www.benzinga.com/quote/HSCS"> has a 52-week low </a> of $0.20.</li>
<li>RSI Value: 26.80</li>
<li>HSCS Price Action: Shares of Heart Test Laboratories fell 8.2% to close at $0.21 on Thursday.</li>
</ul>
<h3>SINTX Technologies Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>)</h3>
<ul>
<li>SINTX Technologies was awarded Phase II NIH grant of $1,972,826 for silicon nitride-PEEK 3D printed composite spinal implants. The company&rsquo;s stock has a 52-week <a href="https://www.benzinga.com/quote/SINT"> low of $0.40.</a></li>
<li>RSI Value: 28.18</li>
<li>SINT Price Action: Shares of SINTX Technologies fell 6.9% to close at $0.42 on Thursday.</li>
</ul>
<h3>Evelo Biosciences Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>)</h3>
<ul>
<li>Evelo Biosciences reported the primary endpoint in its Phase 2 clinical study with EDP2939 in moderate psoriasis was not achieved. The company also initiated a process to explore strategic alternatives. The company&rsquo;s 52-week low is $0.30.</li>
<li>RSI Value: 15.98</li>
<li>EVLO Price Action: Shares of Evelo Biosciences fell 19.4% to close at $0.31 on Thursday.</li>
</ul>
<h3>Arcutis Biotherapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arqt#NASDAQ">ARQT</a>)</h3>
<ul>
<li>Arcutis Biotherapeutics announced the pricing of a $100 million public offering of 32.5 million common shares at $2.50 per share. The company <a href="https://www.benzinga.com/quote/ARQT"> has a 52-week low </a> of $2.13.</li>
<li>RSI Value: 21.70</li>
<li>ARQT Price Action: Shares of Arcutis Biotherapeutics fell 1.8% to close at $2.22 on Thursday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/23/11/35584656/fear-greed-index-remains-in-fear-zone-dow-notches-best-day-since-june"> Fear &amp; Greed Index Remains In &#39;Fear&#39; Zone; Dow Notches Best Day Since June </a>

Long Ideas

ARQT

BTTX

SINT

Top 5 Health Care Stocks That Are Preparing To Pump In November

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30.</a>
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>Spruce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprb#NASDAQ">SPRB</a>)</h3>
<ul>
<li>Spruce Biosciences completed target enrollment of CAHmelia-203 study in adult classic congenital adrenal hyperplasia. The company&rsquo;s stock has a <a href="https://www.benzinga.com/quote/SPRB">52-week low of $0.9550 </a>.</li>
<li>RSI Value: 27.25</li>
<li>SPRB Price Action: Shares of Spruce Biosciences fell 14.2% to close at $1.18 on Thursday.</li>
</ul>
<h3>Generation Bio Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbio#NASDAQ">GBIO</a>)</h3>
<ul>
<li>TD Cowen downgraded the stock from Outperform to Market Perform. It <a href="https://www.benzinga.com/quote/GBIO"> has a 52-week low </a> of $1.17.</li>
<li>RSI Value: 16.32</li>
<li>GBIO Price Action: Shares of Generation Bio dipped 50.2% to close at $1.20 on Thursday.</li>
</ul>
<h3>LumiraDx Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmdx#NASDAQ">LMDX</a>)</h3>
<ul>
<li>LumiraDx posted downbeat results for the second quarter. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, &quot;The submission of our first 510(k) application to the FDA for our COVID Ultra test represents a significant milestone in our ability to deliver on product expansion into the U.S. and could pave the way for additional submissions of other high performing assays on our Platform, many of which are already available in Europe and elsewhere and others which are in late stages of development.&quot; The company&rsquo;s stock has a 52-week <a href="https://www.benzinga.com/quote/LMDX"> low of $0.0850.</a></li>
<li>RSI Value: 19.64</li>
<li>LMDX Price Action: Shares of LumiraDx fell 11.3% to close at $0.0930 on Thursday.</li>
</ul>
<h3>Evelo Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>)</h3>
<ul>
<li>Evelo Biosciences reported the primary endpoint in its Phase 2 clinical study with EDP2939 in moderate psoriasis was not achieved. The company also initiated a process to explore strategic alternatives. The company&rsquo;s 52-week low is $0.48.</li>
<li>RSI Value: 20.36</li>
<li>EVLO Price Action: Shares of Evelo Biosciences fell 11.2% to close at $0.8883 on Thursday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/23/10/35326531/vertex-pharmaceuticals-gilead-sciences-and-2-other-stocks-insiders-are-selling"> Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling </a>

Pre-Market Outlook

GBIO

LMDX

SPRB

Top 4 Health Care Stocks That May Rocket Higher This Month

<h3>Gainers</h3>
<ul>
<li>Atreca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCEL#NASDAQ">BCEL</a>) shares moved upwards by 54.2% to $0.42 during Wednesday's after-market session. This security traded at a volume of 6.3 million shares come close, making up 485.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $16.4 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares increased by 10.12% to $0.43. The market value of their outstanding shares is at $1.4 million. </li>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock increased by 9.17% to $0.56. The market value of their outstanding shares is at $43.5 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares increased by 8.85% to $0.44. The company's market cap stands at $67.0 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock increased by 8.66% to $1.0. The company's market cap stands at $28.9 million. </li>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) shares increased by 8.07% to $1.07. Today's trading volume for this security ended up closing at 75.2K shares, which is 14.0 percent of its average volume over the last 100 days. The company's market cap stands at $20.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nemaura Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRD#NASDAQ">NMRD</a>) shares decreased by 9.6% to $0.28 during Wednesday's after-market session. The company's market cap stands at $7.9 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) stock declined by 8.0% to $0.3. This security traded at a volume of 997.5K shares come close, making up 111.2% of its average volume over the last 100 days. The company's market cap stands at $5.1 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares decreased by 6.7% to $0.53. Today's trading volume for this security ended up closing at 146.4K shares, which is 5.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $6.0 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares decreased by 6.25% to $0.9. The market value of their outstanding shares is at $21.5 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares fell 6.02% to $0.71. Tiziana Life Sciences's trading volume hit 168.5K shares by close, accounting for 26.8% of its average volume over the last 100 days. The company's market cap stands at $71.4 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares decreased by 5.75% to $0.5. The market value of their outstanding shares is at $1.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

AKLI

BCEL

BPTH

HLTH

NMRD

NMTC

TLSA

12 Health Care Stocks Moving In Wednesday's After-Market Session

WIIM

Evelo Biosciences shares are trading lower after TD Cowen downgraded the stock from Outperform to Market Perform.

<h3>Upgrades</h3>
According to National Bank Financial Inc, the prior rating for Brookfield Infrastructure Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIP#NYSE">BIP</a>) was changed from Sector Perform to Outperform. Brookfield Infr Partners earned $0.38 in the second quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $38.18 and a 52-week-low of $24.95. Brookfield Infr Partners closed at $25.69 at the end of the last trading period. 
For FB Financial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>), Janney Montgomery Scott upgraded the previous rating of Neutral to Buy. In the third quarter, FB Financial showed an EPS of $0.71, compared to $0.68 from the year-ago quarter. At the moment, the stock has a 52-week-high of $44.10 and a 52-week-low of $24.34. FB Financial closed at $28.72 at the end of the last trading period. 
For Huntsman Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>), B of A Securities upgraded the previous rating of Underperform to Buy. Huntsman earned $0.22 in the second quarter, compared to $1.21 in the year-ago quarter. The stock has a 52-week-high of $33.46 and a 52-week-low of $22.71. At the end of the last trading period, Huntsman closed at $23.98. 
For LyondellBasell Industries NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>), B of A Securities upgraded the previous rating of Underperform to Neutral. In the second quarter, LyondellBasell Industries showed an EPS of $2.44, compared to $5.19 from the year-ago quarter. The stock has a 52-week-high of $102.05 and a 52-week-low of $75.64. At the end of the last trading period, LyondellBasell Industries closed at $94.75. 
B of A Securities upgraded the previous rating for Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Underperform to Neutral. For the second quarter, Dow had an EPS of $0.75, compared to year-ago quarter EPS of $2.31. At the moment, the stock has a 52-week-high of $60.88 and a 52-week-low of $44.90. Dow closed at $50.73 at the end of the last trading period. 
For First Watch Restaurant Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>), Raymond James upgraded the previous rating of Outperform to Strong Buy. For the second quarter, First Watch Restaurant Gr had an EPS of $0.13, compared to year-ago quarter EPS of $0.05. At the moment, the stock has a 52-week-high of $20.31 and a 52-week-low of $12.80. First Watch Restaurant Gr closed at $16.86 at the end of the last trading period. 
According to Raymond James, the prior rating for Brinker International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) was changed from Outperform to Strong Buy. Brinker International earned $1.39 in the fourth quarter, compared to $1.15 in the year-ago quarter. The stock has a 52-week-high of $42.12 and a 52-week-low of $26.78. At the end of the last trading period, Brinker International closed at $33.65. 
According to Hovde Group, the prior rating for FB Financial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) was changed from Market Perform to Outperform. For the third quarter, FB Financial had an EPS of $0.71, compared to year-ago quarter EPS of $0.68. At the moment, the stock has a 52-week-high of $44.10 and a 52-week-low of $24.34. FB Financial closed at $28.72 at the end of the last trading period. 
According to JP Morgan, the prior rating for Editas Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) was changed from Underweight to Neutral. For the second quarter, Editas Medicine had an EPS of $0.56, compared to year-ago quarter EPS of $0.78. The current stock performance of Editas Medicine shows a 52-week-high of $14.22 and a 52-week-low of $6.33. Moreover, at the end of the last trading period, the closing price was at $6.81. 
According to Mizuho, the prior rating for Hudson Pacific Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) was changed from Underperform to Neutral. In the second quarter, Hudson Pacific Properties showed an EPS of $0.24, compared to $0.51 from the year-ago quarter. The current stock performance of Hudson Pacific Properties shows a 52-week-high of $12.22 and a 52-week-low of $4.04. Moreover, at the end of the last trading period, the closing price was at $5.82. 
Jefferies upgraded the previous rating for Elastic NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from Hold to Buy. Elastic earned $0.25 in the first quarter, compared to $0.15 in the year-ago quarter. The stock has a 52-week-high of $83.35 and a 52-week-low of $46.18. At the end of the last trading period, Elastic closed at $80.64. 
Wolfe Research upgraded the previous rating for Broadstone Net Lease Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) from Peer Perform to Outperform. In the second quarter, Broadstone Net Lease showed an EPS of $0.35, compared to $0.35 from the year-ago quarter. At the moment, the stock has a 52-week-high of $18.54 and a 52-week-low of $13.89. Broadstone Net Lease closed at $14.92 at the end of the last trading period. 
According to Raymond James, the prior rating for Nkarta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) was changed from Outperform to Strong Buy. For the second quarter, Nkarta had an EPS of $0.68, compared to year-ago quarter EPS of $0.61. The stock has a 52-week-high of $13.80 and a 52-week-low of $1.28. At the end of the last trading period, Nkarta closed at $3.14. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
<h3>Downgrades</h3>
For Freeline Therapeutics Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRLN#NASDAQ">FRLN</a>), Wedbush downgraded the previous rating of Outperform to Neutral. For the second quarter, Freeline Therapeutics had an EPS of $0.21, compared to year-ago quarter EPS of $14.25. At the moment, the stock has a 52-week-high of $12.00 and a 52-week-low of $2.11. Freeline Therapeutics closed at $4.32 at the end of the last trading period. 
Scotiabank downgraded the previous rating for Olink Holding AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLK#NASDAQ">OLK</a>) from Sector Outperform to Sector Perform. In the second quarter, Olink Holding showed an EPS of $0.07, compared to $0.04 from the year-ago quarter. The stock has a 52-week-high of $26.47 and a 52-week-low of $14.10. At the end of the last trading period, Olink Holding closed at $24.87. 
For Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>), B of A Securities downgraded the previous rating of Neutral to Underperform. Sherwin-Williams earned $3.29 in the second quarter, compared to $2.41 in the year-ago quarter. The stock has a 52-week-high of $283.80 and a 52-week-low of $199.22. At the end of the last trading period, Sherwin-Williams closed at $252.84. 
For Albemarle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>), B of A Securities downgraded the previous rating of Neutral to Underperform. Albemarle earned $7.33 in the second quarter, compared to $3.45 in the year-ago quarter. The current stock performance of Albemarle shows a 52-week-high of $334.20 and a 52-week-low of $152.00. Moreover, at the end of the last trading period, the closing price was at $169.48. 
For Westlake Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>), B of A Securities downgraded the previous rating of Neutral to Underperform. Westlake earned $2.31 in the second quarter, compared to $6.60 in the year-ago quarter. The stock has a 52-week-high of $138.39 and a 52-week-low of $87.94. At the end of the last trading period, Westlake closed at $125.11. 
B of A Securities downgraded the previous rating for Sociedad Quimica Y Minera De Chile SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) from Neutral to Underperform. For the second quarter, Sociedad Quimica Y Minera had an EPS of $2.03, compared to year-ago quarter EPS of $3.01. The current stock performance of Sociedad Quimica Y Minera shows a 52-week-high of $112.34 and a 52-week-low of $52.42. Moreover, at the end of the last trading period, the closing price was at $59.45. 
B of A Securities downgraded the previous rating for ArcelorMittal SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>) from Buy to Neutral. In the second quarter, ArcelorMittal showed an EPS of $2.20, compared to $4.24 from the year-ago quarter. The stock has a 52-week-high of $32.48 and a 52-week-low of $21.15. At the end of the last trading period, ArcelorMittal closed at $23.34. 
B of A Securities downgraded the previous rating for Sibanye Stillwater Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) from Neutral to Underperform. NoneThe stock has a 52-week-high of $12.44 and a 52-week-low of $5.16. At the end of the last trading period, Sibanye Stillwater closed at $6.15. 
According to TD Cowen, the prior rating for Evelo Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) was changed from Outperform to Market Perform. Evelo Biosciences earned $3.78 in the second quarter, compared to $8.00 in the year-ago quarter. At the moment, the stock has a 52-week-high of $48.00 and a 52-week-low of $0.49. Evelo Biosciences closed at $1.20 at the end of the last trading period. 
RBC Capital downgraded the previous rating for Sibanye Stillwater Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) from Outperform to Sector Perform. NoneAt the moment, the stock has a 52-week-high of $12.44 and a 52-week-low of $5.16. Sibanye Stillwater closed at $6.15 at the end of the last trading period. 
According to Deutsche Bank, the prior rating for Lithium Americas Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAC#NYSE">LAC</a>) was changed from Buy to Hold. For the second quarter, Lithium Americas had an EPS of $0.16, compared to year-ago quarter EPS of $0.12. At the moment, the stock has a 52-week-high of $29.48 and a 52-week-low of $8.50. Lithium Americas closed at $9.10 at the end of the last trading period. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h3>Initiations</h3>
With a Market Perform rating, TD Cowen initiated coverage on WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>). The price target seems to have been set at $11.00 for WK Kellogg. The stock has a 52-week-high of $21.00 and a 52-week-low of $9.65. At the end of the last trading period, WK Kellogg closed at $10.10. 
Jefferies initiated coverage on Pinterest Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Hold rating. The price target for Pinterest is set to $30.00. In the second quarter, Pinterest showed an EPS of $0.21, compared to $0.11 from the year-ago quarter. At the moment, the stock has a 52-week-high of $30.86 and a 52-week-low of $20.60. Pinterest closed at $28.00 at the end of the last trading period. 
With a Buy rating, Redburn Atlantic initiated coverage on Nu Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>). The price target seems to have been set at $11.00 for Nu Holdings. In the second quarter, Nu Holdings showed an EPS of $0.05, compared to $0.01 from the year-ago quarter. The stock has a 52-week-high of $8.29 and a 52-week-low of $3.39. At the end of the last trading period, Nu Holdings closed at $7.88. 
With an Overweight rating, Keybanc initiated coverage on ARM Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>). The price target seems to have been set at $65.00 for ARM Holdings. The stock has a 52-week-high of $69.00 and a 52-week-low of $49.85. At the end of the last trading period, ARM Holdings closed at $52.29. 
With a Market Outperform rating, JMP Securities initiated coverage on Vigil Neuroscience Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>). The price target seems to have been set at $23.00 for Vigil Neuroscience. For the second quarter, Vigil Neuroscience had an EPS of $0.52, compared to year-ago quarter EPS of $0.60. The stock has a 52-week-high of $16.50 and a 52-week-low of $4.68. At the end of the last trading period, Vigil Neuroscience closed at $6.58. 
JMP Securities initiated coverage on Notable Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTBL#NASDAQ">NTBL</a>) with a Market Outperform rating. The price target for Notable Labs is set to $13.00. The stock has a 52-week-high of $5.27 and a 52-week-low of $2.85. At the end of the last trading period, Notable Labs closed at $4.45. 
With a Buy rating, Berenberg initiated coverage on Alpine Immune Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALPN#NASDAQ">ALPN</a>). The price target seems to have been set at $18.00 for Alpine Immune Sciences. Alpine Immune Sciences earned $0.27 in the second quarter, compared to $0.60 in the year-ago quarter. At the moment, the stock has a 52-week-high of $14.92 and a 52-week-low of $4.83. Alpine Immune Sciences closed at $10.20 at the end of the last trading period. 
Deutsche Bank initiated coverage on Lithium Americas (Argentina) Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAAC#NYSE">LAAC</a>) with a Buy rating. The price target for Lithium Americas is set to $11.00. The stock has a 52-week-high of $8.14 and a 52-week-low of $5.07. At the end of the last trading period, Lithium Americas closed at $6.99. 
Stifel initiated coverage on TeraWulf Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) with a Buy rating. The price target for TeraWulf is set to $3.00. In the second quarter, TeraWulf showed an EPS of $0.08, compared to $0.13 from the year-ago quarter. The stock has a 52-week-high of $4.04 and a 52-week-low of $0.54. At the end of the last trading period, TeraWulf closed at $1.24. 
With a Buy rating, Stifel initiated coverage on Vestis Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>). The price target seems to have been set at $20.00 for Vestis. The current stock performance of Vestis shows a 52-week-high of $19.31 and a 52-week-low of $14.23. Moreover, at the end of the last trading period, the closing price was at $15.89. 
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Analyst Ratings

ALPN

EDIT

ESTC

FRLN

FWRG

LAAC

NKTX

NTBL

PINS

SBSW

VSTS

WULF

Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023

TD Cowen analyst Joseph Thome downgrades Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) from Outperform to Market Perform.

TD Cowen Downgrades Evelo Biosciences to Market Perform

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday.
The Dow traded down 0.09% to 33,954.39 while the NASDAQ fell 0.37% to 13,517.59. The S&amp;P 500 also fell, dropping, 0.10% to 4,369.41.
Check This Out: <a href="https://www.benzinga.com/news/23/10/35284576/accenture-robinhood-and-2-other-stocks-insiders-are-selling"> Accenture, Robinhood And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Materials shares climbed by 1% on Tuesday.
In trading on Tuesday, information technology shares fell by 0.4%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Bank of America Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bac#NYSE">BAC</a>) reported better-than-expected earnings for its third quarter on Tuesday.
The bank said EPS for the quarter was $0.90, compared to $0.81 in the year-ago period, beating the consensus of $0.81. Revenue increased 3% year-over-year to $25.32 billion, beating the consensus of $25.14 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) shares shot up 122% to $6.28. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
Shares of Assembly Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asmb#NASDAQ">ASMB</a>) got a boost, shooting 80% to $1.3101 after the company and Gilead announced they entered into a 12-year partnership to advance the research and development of novel antiviral therapies.
Olink Holding AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olk#NASDAQ">OLK</a>) shares were also up, gaining 67% to $24.95 after Thermo Fisher Scientific announced it will acquire the company.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Evelo Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>) shares dropped 56% to $1.2694. Evelo Biosciences released top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis.
Shares of NetScout Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntct#NASDAQ">NTCT</a>) were down 16% to $23.17 after the company reported weak preliminary results for the second quarter and lowered its FY24 guidance.
Monte Rosa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glue#NASDAQ">GLUE</a>) was down, falling 18% to $4.09 as the company announced interim data from the Phase 1 dose escalation part of its ongoing phase 1/2 study of MRT-2359 in patients with MYC-driven solid tumors.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/10/35284015/top-4-defensive-stocks-which-could-rescue-your-portfolio-this-month"> Top 4 Defensive Stocks Which Could Rescue Your Portfolio This Month</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.5% to $86.23 while gold traded up 0.1% at $1,936.90.
Silver traded up 1.4% to $23.08 on Tuesday while copper fell 0.1% to $3.5805.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed mostly higher today. The eurozone&rsquo;s STOXX 600 fell 0.10%, London&rsquo;s FTSE 100 rose 0.58% while Spain&rsquo;s IBEX 35 Index rose 0.12% The German DAX rose 0.09% French CAC 40 rose 0.11%, while Italy&rsquo;s FTSE MIB Index slipped 0.09%.
The ZEW Indicator of Economic Sentiment for the Eurozone rose to 2.3 in October from -8.9 in a month ago. The ZEW Indicator of Economic Sentiment for Germany climbed by 10.3 points to a reading of -1.1 in October.
Average weekly earnings, including bonuses in the UK, rose 8.1% year-over-year to GBP 661/week during the three months to August. UK&rsquo;s number of job vacancies fell to 988,000 in the third quarter.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 1.20%, China&rsquo;s Shanghai Composite Index gaining 0.32% and Hong Kong&rsquo;s Hang Seng Index gaining 0.75%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.4%.
Total passenger vehicle sales in India climbed by 3.1% year-over-year to 316,908 in September. Singapore&#39;s non-oil domestic exports declined by 13.2% year-over-year in September following a revised 22.5% decline in August.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. retail sales rose 0.7% month-over-month in September versus a revised 0.8% increase in August and topping estimates of a 0.3% increase.
U.S. industrial production rose 0.3% month-over-month in September, beating market expectations for a flat reading.
The NAHB/Wells Fargo Housing Market Index declined by 4 points to 40 in October, missing market estimates of 44.
Total business inventories rose by 0.4% month-over-month in August versus a revised 0.1% increase a month ago.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/10/35284435/these-3-materials-stocks-delivering-high-dividend-yields-are-recommended-by-wall-streets"> These 3 Materials Stocks Delivering High-Dividend Yields Are Recommended By Wall Street&#39;s Most Accurate Analysts</a>

ASMB

GLUE

NTCT

Crude Oil Moves Lower; Bank of America Profit Beats Expectations

<h3>Gainers</h3>
<ul>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.</li>
<li>Assembly Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asmb#NASDAQ">ASMB</a>) gained 120% to $1.5982 after the company and Gilead announced they entered into a 12-year partnership to advance the research and development of novel antiviral therapies.</li>
<li>Olink Holding AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olk#NASDAQ">OLK</a>) shares climbed 65.8% to $24.84 after Thermo Fisher Scientific announced it will acquire the company.</li>
<li>MoneyHero Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mny#NASDAQ">MNY</a>) surged 33.7% to $3.40.</li>
<li>OpGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opgn#NASDAQ">OPGN</a>) gained 32.7% to $1.20.</li>
<li>FLJ Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flj#NASDAQ">FLJ</a>) jumped 29.3% to $0.2689.</li>
<li>Anebulo Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aneb#NASDAQ">ANEB</a>) gained 22.5% to $2.0950.</li>
<li>Ramaco Resources, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/metc#NASDAQ">METC</a>) rose 20.2% to $11.73.</li>
<li>Aurora Mobile Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jg#NASDAQ">JG</a>) shares climbed 19.8% to $0.1593 after gaining 8% on Monday.</li>
<li>Nkarta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktx#NASDAQ">NKTX</a>) rose 18.5% to $1.75 as the company received FDA clearance of IND application for NKX019 in lupus nephritis.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) gained 18% to $3.0905.</li>
<li>Gamer Pakistan Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gpak#NASDAQ">GPAK</a>) gained 16.8% to $1.46.</li>
<li>Summit Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smmt#NASDAQ">SMMT</a>) rose 16% to $2.03.</li>
<li>Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares rose 15.4% to $0.1062 after falling 4% on Monday.</li>
<li>WiSA Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wisa#NASDAQ">WISA</a>) shares gained 12.8% to $0.28 after falling 40% on Monday. WiSA Technologies announced pricing of $4.8 million public offering of Series B convertible redeemable preferred stock and warrants.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/itos#NASDAQ">ITOS</a>) jumped 12.8% to $9.77.</li>
<li>Athersys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athx#NASDAQ">ATHX</a>) shares gained 12.3% to $0.1102. Athersys extended near term liquidity with proceeds from warrant inducement and global ARDS license with Healios to explore strategic alternatives.</li>
<li>Moolec Science SA (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlec#NASDAQ">MLEC</a>) climbed 12% to $2.80. Moolec Science secured $21 million investment from Grupo Insud, bolstering its food ingredient innovations.</li>
<li>V.F. Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vfc#NYSE">VFC</a>) gained 10.1% to $17.82. Engaged Capital has built a big stake in VF Corp, according to the Wall Street Journal.</li>
<li>AGBA Group Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agba#NASDAQ">AGBA</a>) rose 8.9% to $0.5336.</li>
<li>Cytek Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctkb#NASDAQ">CTKB</a>) gained 8.6% to $5.24.</li>
<li>Under Armour, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uaa#NYSE">UAA</a>) rose 7.3% to $7.51.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Evelo Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>) shares fell 50.2% to $1.4501. Evelo Biosciences released top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis.</li>
<li>Monte Rosa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glue#NASDAQ">GLUE</a>) fell 19.9% to $4.0050 as the company announced interim data from the Phase 1 dose escalation part of its ongoing phase 1/2 study of MRT-2359 in patients with MYC-driven solid tumors.</li>
<li>Nuvve Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvve#NASDAQ">NVVE</a>) fell 19.1% to $0.3161 after gaining over 9% on Monday.</li>
<li>NetScout Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntct#NASDAQ">NTCT</a>) fell 18.2% to $22.58 after the company reported weak preliminary results for the second quarter and lowered its FY24 guidance.</li>
<li>BIO-key International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bkyi#NASDAQ">BKYI</a>) fell 17.4% to $0.4299 after the company filed for offering of units of up to $10 million.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpth#NASDAQ">BPTH</a>) declined 16.5% to $0.5678.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) fell 10.4% to $1.2187.</li>
<li>DXC Technology Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxc#NYSE">DXC</a>) fell 9.9% to $20.05 after Wolfe Research downgraded the stock from Peer Perform to Underperform.</li>
<li>The Vita Coco Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coco#NASDAQ">COCO</a>) fell 9.7% to $24.29.</li>
<li>Ambrx Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amam#NASDAQ">AMAM</a>) fell 8.7% to $10.44 after declining 19% on Monday. Ambrx Biopharma announced that two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic castration-resistant prostate cancer (mCRPC) were made available as part of the 2023 European Society of Medical Oncology Congress 2023 meeting.</li>
<li>Rani Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rani#NASDAQ">RANI</a>) fell 8.5% to $2.01 after gaining 11% on Monday.</li>
<li>Nvni Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvni#NASDAQ">NVNI</a>) fell 8.4% to $3.18.</li>
<li>VMware, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vmw#NYSE">VMW</a>) fell 7% to $166.33.</li>
<li>ServisFirst Bancshares, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfbs#NASDAQ">SFBS</a>) declined 6.1% to $49.65 after the company reported third-quarter earnings.</li>
<li>22nd Century Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NASDAQ">XXII</a>) shares fell 5.4% to $0.5201 after the company reported pricing of $5.25 million public offering.</li>
<li>NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) declined 4.6% to $439.95. The U.S. government divulged plans to halt shipments to China of more advanced AI chips designed by Nvidia and others, citing military threats.</li>
<li>The Bank of New York Mellon Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bk#NYSE">BK</a>) fell 4.5% to $39.99 following third-quarter results.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eric#NASDAQ">ERIC</a>) shares fell 3.6% to $4.5899 after the company reported downbeat third-quarter sales. Ericsson expects lower than-normal seasonality in sales between Q3 and Q4 for Networks and Cloud Software and Services.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/10/35280330/how-to-earn-500-a-month-from-charles-schwab-stock-following-q3-earnings"> How To Earn $500 A Month From Charles Schwab Stock Following Q3 Earnings</a>

AGBA

AGRI

AMAM

ANEB

ATHX

BKYI

COCO

CTKB

ERIC

GPAK

ITOS

LXRX

Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Comments

Evelo Biosciences

Evelo Biosciences (EVLO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO